Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
about
Untangling tau imagingThe end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspectiveImaging frontotemporal lobar degeneration.Mutant amyloid precursor protein differentially alters adipose biology under obesogenic and non-obesogenic conditions.Amyloid-β positron emission tomography imaging probes: a critical review.Washout allometric reference method (WARM) for parametric analysis of [(11)C]PIB in human brainsPiB Fails to Map Amyloid Deposits in Cerebral Cortex of Aged Dogs with Canine Cognitive Dysfunction.Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque.Natural polyphenols binding to amyloid: a broad class of compounds to treat different human amyloid diseases.Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET.Disaggregation-induced fluorescence enhancement of NIAD-4 for the optical imaging of amyloid-β fibrils.Biomathematical screening of amyloid radiotracers with clinical usefulness index.Synthesis and evaluation of (13)N-labelled azo compounds for β-amyloid imaging in mice.Investigation of (11)C-PiB equivocal PET findings.Label-free imaging of amyloid plaques in Alzheimer's disease with stimulated Raman scattering microscopy
P2860
Q26739091-DFCD309B-FEFA-4B31-8F10-8F8737431671Q27014294-433A7CB4-50F3-4297-8373-C69B7FDAD3B1Q30846573-CCFAA191-1A3D-4CEB-8C0D-91286AD5415DQ34389397-8768B0D7-D9F2-4647-A8B5-1C08591C22E4Q37086266-6A4949E5-9D1F-4070-8F7A-76D2328FFD93Q37346940-7D6A84CC-AA65-439D-9C56-F255C061017FQ37417915-5D1CAA8B-4B62-4047-BA70-F9448D1FBA17Q37498339-2CB01153-43FF-4186-8697-41920719BCC0Q38170338-035923D8-CBE4-48A2-85C5-29A3D0195A78Q38244247-1DD9519F-019D-4E61-B745-01B124F93698Q45732943-42A6D9C6-84A8-4A8D-8FCF-2CF667CE4AC1Q46707533-3ADB4A44-432B-4FB3-8102-36FD6AE66B97Q47241835-54A1E059-A613-48AF-AA99-B28FABECDCFEQ48823625-52230805-B988-467B-B0C7-C4237BFA22F9Q53042095-73DF00CC-AE1B-4B95-93EB-8D9A29C59B3BQ59136630-3B285FE8-A7BF-4CBA-A0CC-7D685AAE9C60
P2860
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
@en
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
@nl
type
label
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
@en
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
@nl
altLabel
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease
@en
prefLabel
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
@en
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
@nl
P2093
P2860
P50
P1476
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
@en
P2093
Alexander Drzezga
Chester A Mathis
Christopher C Rowe
Dennis J Selkoe
John C Morris
Keith A Johnson
Kenji Ishii
Koen Van Laere
Milos D Ikonomovic
Reisa A Sperling
P2860
P2888
P304
P356
10.1007/S00259-011-2045-0
P407
P50
P577
2012-02-01T00:00:00Z